The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1750 participants.
Also called NCT05374291
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 1,750 participants
- Registry
-
NCT05374291 -
2021-005446-15 -
2023-508389-13-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia, Belgium, Germany, Netherlands, Singapore, Spain
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05374291. Randomized; double masking; primary purpose prevention. Start 2022-11-08 (actual); primary completion 2027-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
- Condition
- Kidney Disease, Chronic
- Condition
- Renal Transplant Failure
- Condition
- Heart Failure
- Condition
- Kidney Failure
- Condition
- Death
- Intervention (Drug)
- Dapagliflozin 10 mg/day (oral)
- Intervention (Drug)
- Placebo
- Lead sponsor
- University Medical Center Groningen
- Collaborator
- AstraZeneca
- Collaborator
- Dutch Kidney Foundation
Record details
- Record id
cardio:ct-nct05374291- Content hash
46775ac8d7bbb8a64c18ec74e9855d6184e1ef26570512edb79a09114d476f0a